Ibio Inc. (IBIO) stock prices were down by 1.50% as of the market closing on October 13th 2021. This brought the price per share down to USD$0.93 at the end of the trading day. Subsequent premarket fluctuations have seen the stock dip by 9.56%, bringing it down to USD$0.84.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Setting the Stage for 2022
Fiscal 2021 turned out to be a transformative year for IBIO stock, marked by its entry into oncology and continued development as a next generation Covid-19 vaccine developer. The oncology drug discover team was established in San Diego, subsequent to which the company entered into a partnership with FairJourney Biologics. The partnership will provide the company with access to proprietary antibodies and announced the addition of three new anti-cancer targets to its pipeline. August 2021 saw the company announce an exclusive license agreement with RybrYc Therapeutics. This partnership was for a second generation anti-CD25 antibody for the treatment of solid tumors, while also providing the company access to its partner’s AI-driven antibody discovery platform. This partnership will enable the company to develop multiple novel immuno-oncology targets.
IBIO Stock Address Pandemic
In conjunction with IBIO stock’s FastPharming and Glycaneering Technologies, the company finds itself adequately situated to leverage extensive discovery and development synergies across its proprietary platforms. This will enable the company to continue expanding on the development of its pipeline of differentiated, next generation oncology therapeutics. The company’s IBIO-202 Covid-19 vaccine is being developed with the belief that there is an essential need to design vaccines that target regions besides the typical mutating spike protein. This will further address the looming risk of the emergence of a variant that is resistant to most existing vaccines.
The company grew its Bioprocess segment concurrent to the aggressive development of its Biopharmaceutical segment and the recruitment of a new Management Team. Revenues in the Services business for the 2021 year reported a 50% increase over the prior year. The company also established a new Products business unit to further leverage its FastPharming System and capabilities to deliver greener products to researchers and biomanufacturers.
Future Outlook for IBIO Stock
The company reported a promising fiscal 2021 year, as evidenced by the strength of its financial reports for the fourth quarter of fiscal 2021. IBIO stock is keen to maintain the momentum it has generated through the upcoming fiscal 2022 quarters. Current and potential investors are hopeful that management will be able to effectively leverage the resources at their disposal. This is hoped to facilitate consistent and organic increases in shareholder value over the long term.